INDOCO — INDOCO REMEDIES Share Price
0.000.00%
Last trade - 00:00- IN₹21.30bn
- IN₹29.19bn
- IN₹18.17bn
- 54
- 27
- 47
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 30.79 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 0.99% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.97 | ||
| Price to Tang. Book | 2.37 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.24 | ||
| EV to EBITDA | 17.29 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.67% | ||
| Return on Equity | -0.99% | ||
| Operating Margin | 3.38% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 11,065.81 | 12,415.28 | 15,407.53 | 16,686.11 | 18,172.87 | 17,040.67 | 19,469.33 | 13.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +248.74 | +67.65 | -8.48 | -36.8 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products for the Indian and international markets. In the international market, it has tie-ups with generic companies across the globe. It has approximately eight domestic marketing divisions, with a brand portfolio in various therapeutic segments including gastro-intestinal, respiratory, anti-infective, stomatologicals, ophthalmic, nutritionals, cardiovascular, anti-diabetics, pain management, gynecology and others. The Company's brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral and Rexidin. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.
Directors
- Suresh Kare CHM
- Aditi Panandikar CEO (51)
- Pramod Ghorpade CFO
- Mangesh Rajadhyaksha CEX
- Jayshankar Menon CCO
- Sundeep Bambolkar MDR (61)
- Anand Nadkarni NED (56)
- Divakar Gavaskar NID (78)
- Abhijit Gore NID (55)
- Rajiv Kakodkar NID (58)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 23rd, 1947
- Public Since
- January 7th, 2005
- No. of Shareholders
- 33,797
- No. of Employees
- 5,931
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 92,220,755
- Address
- 166 Indoco House, MUMBAI, 400098
- Web
- https://www.indoco.com/
- Phone
- +91 2226541851
- Contact
- Pramod Ghorpade
- Auditors
- Gokhale & Sathe
Upcoming Events for INDOCO
Q1 2026 Indoco Remedies Ltd Earnings Release
Indoco Remedies Ltd Annual Shareholders Meeting
Q2 2026 Indoco Remedies Ltd Earnings Release
Similar to INDOCO
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the INDOCO REMEDIES share price?
As of Today at 21:17 UTC, shares in INDOCO REMEDIES are trading at IN₹232.48. This share price information is delayed by 15 minutes.
How has the INDOCO REMEDIES share price performed this year?
Shares in INDOCO REMEDIES last closed at IN₹232.48 and the price had moved by -28.26% over the past 365 days. In terms of relative price strength the INDOCO REMEDIES share price has underperformed the S&P BSE 100 Index by -32.42% over the past year.
What are the analyst and broker recommendations for INDOCO REMEDIES?
The overall consensus recommendation for INDOCO REMEDIES is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the INDOCO REMEDIES dividend yield?
The INDOCO REMEDIES dividend yield is 0.65% based on the trailing twelve month period.
Does INDOCO REMEDIES pay a dividend?
Last year, INDOCO REMEDIES paid a total dividend of IN₹1.50, and it currently has a trailing dividend yield of 0.65%. We do not have any data on when INDOCO REMEDIES is to next pay dividends.
When does INDOCO REMEDIES next pay dividends?
We do not have data on when INDOCO REMEDIES is to next pay dividends. The historic dividend yield on INDOCO REMEDIES shares is currently 0.65%.
How do I buy INDOCO REMEDIES shares?
To buy shares in INDOCO REMEDIES you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of INDOCO REMEDIES?
As of the previous close price of IN₹232.48, shares in INDOCO REMEDIES had a market capitalisation of IN₹21.30bn.
Where are INDOCO REMEDIES shares listed?
Here are the trading details for INDOCO REMEDIES:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: INDOCO
What kind of share is INDOCO REMEDIES?
Based on an overall assessment of its quality, value and momentum INDOCO REMEDIES is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a INDOCO REMEDIES share price forecast for 2025?
The analyst consensus target price for shares in INDOCO REMEDIES is IN₹317.03. That is 36.37% above the last closing price of IN₹232.48.
Analysts covering INDOCO REMEDIES currently have a consensus Earnings Per Share (EPS) forecast of -IN₹4.85 for the next financial year.
Find out moreWhat is the trend in the INDOCO REMEDIES share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like INDOCO REMEDIES. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -21.91%.
As of the last closing price of IN₹232.48, shares in INDOCO REMEDIES were trading -24.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the INDOCO REMEDIES PE Ratio?
The INDOCO REMEDIES PE ratio based on its reported earnings over the past 12 months is 30.79. The shares last closed at IN₹232.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of INDOCO REMEDIES?
INDOCO REMEDIES' management team is headed by:
- Suresh Kare - CHM
- Aditi Panandikar - CEO
- Pramod Ghorpade - CFO
- Mangesh Rajadhyaksha - CEX
- Jayshankar Menon - CCO
- Sundeep Bambolkar - MDR
- Anand Nadkarni - NED
- Divakar Gavaskar - NID
- Abhijit Gore - NID
- Rajiv Kakodkar - NID